Skip to content
OpenCapital
Get started

ANI Pharmaceuticals ANIP Q4 2025 Annual earnings

Reported February 27, 2026 · Before market open

Revenue$247.1MBeat by $16.0M
EPS$2.33Beat by $0.34
Revenue estimate$231.1M
EPS estimate$1.99

Next report

Aug 7, 2026 (In 1 week)
Revenue estimate$260.1M
EPS estimate$2.01

Financials

Q4 2025

Income statement

See full
Revenue$247.1M+29.6%
Gross profit$146.8M+33.1%
Operating income$34.8M—
Net income$27.5M+368%
EPS (diluted)$1.17+313%

Balance sheet

See full
Cash & equivalents$285.6M+97.1%
Total debt$320.4M-1.4%
Total equity$540.7M+33.9%
Total assets$1.4B+12.1%

Cash flow

See full
Operating cash flow$30.4M+91.5%
CapEx$1.2M-48.0%
Free cash flow$29.1M+116%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$1.77B+52.6%
Enterprise value$1.81B+34.7%
P/E22.6×—
P/S2×+0.1×

Profitability

See full
Gross margin61.4%+2.1pp
Operating margin12.6%—
Net margin8.9%+7.1pp
FCF margin19.4%+11.6pp

Returns & leverage

See full
Return on equity16.6%+13.7pp
Debt / equity0.6×-0.2×
Current ratio2.7×0.0×

Versus estimates

Revenue

Q1 2026$237.5MBeat by $29.8M
Q4 2025$247.1MBeat by $16.0M
Q3 2025$227.8MMiss by $4.4MQ2 2025$211.4MBeat by $2.6MQ1 2025$197.1MBeat by $8.4MQ4 2024$190.6MBeat by $20.6M

Diluted EPS

Q1 2026$2.05Beat by $0.77
Q4 2025$2.33Beat by $0.34
Q3 2025$2.04Beat by $0.30Q2 2025$1.80Beat by $0.42Q1 2025$1.70Beat by $0.33Q4 2024$1.63Beat by $0.22

Ask the moment ANI Pharmaceuticals reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did ANI Pharmaceuticals report Q4 2025 earnings?
ANI Pharmaceuticals (ANIP) reported Q4 2025 earnings on February 27, 2026 before market open.
What were ANI Pharmaceuticals's Q4 2025 revenue and EPS?
ANI Pharmaceuticals reported revenue of $247.1M and eps of $2.33 for Q4 2025.
Did ANI Pharmaceuticals beat estimates in Q4 2025?
Revenue beat the consensus estimate of $231.1M by $16.0M. EPS beat the consensus estimate of $1.99 by $0.34.
How did ANI Pharmaceuticals's Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 29.6% from $190.6M a year earlier and eps grew 42.9% from $1.63.
Where can I find ANI Pharmaceuticals's Q4 2025 SEC filings?
You can read the 8-K earnings release (0001023024-26-000013) and the 10-K periodic report (0001023024-26-000014) directly on SEC EDGAR. The filing index links above go to sec.gov.